期刊文献+

2005~2010年我院抗乙型肝炎病毒核苷类药物应用分析 被引量:5

原文传递
导出
摘要 目的评价我院住院药房抗乙型肝炎病毒(HBV)核苷类药物的应用现状及发展趋势。方法统计并计算2005~2010年住院药房抗乙型肝炎病毒核苷类药物的用药金额、构成比、标准计算用药频度(DDDs)、日均费用(DDDc)等,分析临床用药情况。结果乙型肝炎病毒核苷类药物用药金额及比例呈逐年增长趋势,以2006年增长幅度最大,为151.11%;药品构成比中恩替卡韦呈逐年递增趋势,由2006年的31.50%升至2010年的63.52%;DDDs除恩替卡韦每年递增外,其他各药保持平稳。日均费用排序恩替卡韦位居首位,6年来4种药品的日均费用波动范围很小。结论乙型肝炎病毒核苷类药物应用正逐步规范化,药师应为提高患者依从性发挥作用。
作者 朱晓虹
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第18期1459-1461,共3页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献11

  • 1ZHANG Q, SUN L R. Selective inhibitors of hepartitis B virusreplication [J].中国药学杂志,2006,41(16):1205-1209.
  • 2Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of preven- tion and treatment for chronic hepatitis B[ J]. 中国肝病杂志,2005,13(12):881-891.
  • 3Chinese Society of Hepatology, Chinese Medical AssociationChi- nese Society of Infectious Diseases, Chinese Medical Association. The Guideline of Prevention and Treatment for Chronic HepatitisB(慢性乙型肝炎防治指南)[M].2010:1-12.
  • 4CHEN X Q,JIN Y Y,TANG G. New Materia Medica(新编药物学)[M].Section 17 version, Beijing: People's Health PublishingHouse ,2011 : 128-130.
  • 5LI L, LI Y Z. New drug of anti-hepatitis B virus-entecavir [ J].新药与临床,2006,4(4):56.
  • 6OHISHI W,CHAYAMA K. Treatment of chronic hepatitis B with nucleos(t) ide analogues [ J ]. Hepatol Res, 2012,42 ( 3 ) : 219- 225.
  • 7SONG J C,MIN B Y,KIM J W, et al. Pretreatment serum HB- sAg-to-HBV DNA ratio predicts avirologic response to entecavir in chronic hepatitis B[J]. Korean J Hepatol,2011,17 (4) :268- 273.
  • 8PAN C Q, TONG M, KOWDLEY K V, et al. High rates of viral suppression following long-term entecavir treatment of asianpa- tients with HBeAg-positive chronic hepatitis B[ J]. Clin Gastroen- terol Hepato1,2012,10 ( 9 ) : 1047-1050.
  • 9TSAI M C, LEE C M, CHIU K W, et al. A comparison of telbi- vudine and entecavir for chronic hepatitis B in real-world clinical practice[J].J Antimicrob Chemother , 2012,67 (3) :696-699.
  • 10LIU J. Chronic hepatitis B antiviral treatment status of implemen- tation of survey analysis [ D ]. Zhongshan : Zhongshan University, 2010.

同被引文献35

  • 1庄辉.乙型肝炎流行病学研究进展[J].中国医学前沿杂志(电子版),2009,1(2):18-24. 被引量:91
  • 2Jiang-Shan Lian,Lin-Yan Zeng,Jian-Yang Chen,Hong-Yu Jia,Yi-Min Zhang,Dai-Rong Xiang,Liang Yu,Jian-Hua Hu,Ying-Feng Lu,Ling Zheng,Lan-Juan Li,Yi-Da Yang.De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis[J].World Journal of Gastroenterology,2013,19(37):6278-6283. 被引量:36
  • 3中华医学会肝病学分会.中华医学会感染病分会.慢性乙型肝炎防治指南.中国临床医生,2012,40(4):66-78.
  • 4Ohishi W, Chayama K. Treatment of chronic hepatitis B with nucleos(t)ide analogues[J]. Hepatol Res, 2012, 42(3): 219-225.
  • 5Pan CQ, Tong M, Kowdley KV, et al. High rates of viral suppression after long-term entecavir treatment of Asian patients with HBeAg-positive chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2012, 10(9): 1047-1050.
  • 6Graham CW. Treatment with interferons (including pegylated interferons) in patients with hepatitis B[J]. Semin Liver Dis, 2004, 24 (Suppl 1): 45-53.
  • 7Shin SR,Koh KC,Gwak GY,et al.A low viral load predicts a highe initial virologic response to adefovir in patients with lami-vudine resisitant chronic hepatits B[J].Gut Liver,2010,4(4):530-536.
  • 8Liang X,Bi S,Yang W,et al.Epidemiological serosurvey of B in China-declining HBV Prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47):6550-6557.
  • 9Elefsiniotis IS,Tsoumakas K,Papadakis M,et al.Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection[J].Eur J Intern Med,2011,22(2):182-186.
  • 10Bridges E.Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity,reproductive toxicity or carcinogenicity toxicity[J].Hospital,2006,44:5147.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部